Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Dabrafenib and trametinib price?
Brenzavvy discontinuation?
Mebendazole ingredients?
When is tenofovir alafenamide patent expiring?
Patent term adjustment semaglutida?

Lipitor side effects depression?

See the DrugPatentWatch profile for Lipitor

Can Lipitor (atorvastatin) cause depression?

Depression is listed among potential side effects of statins, including Lipitor, in some sources, but it is not among the most common Lipitor adverse effects. Reports do exist, and the risk is usually described as uncommon and hard to quantify because depression can have many causes. [1]

What side effects are Lipitor more likely to cause instead?

For many people, the more typical reasons for stopping or calling a clinician after starting Lipitor are muscle-related symptoms, abnormal lab results, or other well-known statin effects. Those can include muscle pain or weakness and liver enzyme elevations. [2]

Who is more at risk of mood changes with statins?

People may be more likely to notice mood symptoms if they have other risk factors for depression (for example, prior depression, major stressors, or other medications that affect mood). A direct “who gets it” profile for statin-related depression is not well defined in the available labeling-type information, so clinicians usually rely on individual history and symptom timing. [1][2]

When do symptoms usually start, and what should you do?

If depression symptoms begin soon after starting Lipitor or after a dose change, clinicians often consider whether the timing fits and whether other causes are present. The practical approach is to contact the prescribing clinician promptly rather than stopping the drug on your own, because stopping can remove cardiovascular protection. The clinician may check for other contributors (thyroid issues, vitamin deficiencies, medication interactions) and decide whether to adjust the dose, switch statins, or use another lipid-lowering option. [1][2]

What are the red flags that mean you should seek urgent help?

If depression comes with thoughts of self-harm, severe agitation, or inability to function safely, seek urgent help right away (emergency services or a crisis hotline). Mood symptoms can be serious regardless of the cause.

How do doctors handle it if Lipitor seems to worsen mood?

Common steps include reviewing the start date and dose, checking for interacting medicines, evaluating other medical causes, and considering a trial change (such as dose adjustment or switching to a different statin) if the clinician believes Lipitor is a likely contributor. If statins are not tolerated, non-statin lipid therapies may be considered to maintain cholesterol control. [2]

What do drug labels say about depression?

Drug safety references and product information for statins generally note depression or mood changes as possible adverse effects, though they are not typically the most frequent. [1]

---

Sources

Prescribing Information Alignment Report

Executive Summary

Overall Alignment: Unable to Assess

The provided FDA label excerpts for LIPITOR (atorvastatin calcium) include information on dosing, contraindications, key warnings/precautions, and adverse reactions, but they do not include any statements about depression/mood disorders. Because the supplied excerpts lack the needed labeled content, each AI safety/mood-related claim cannot be evaluated for support, partial support, contradiction, or misalignment.

Alignment Scorecard

Category	Status	Notes
Indication	Unable to Assess	No depression-related claims tied to approved indications in provided excerpts.
Patient Population	Unable to Assess	No labeled population details relevant to depression/mood symptoms in provided excerpts.
Dosage & Administration	Unable to Assess	AI claims are about mood symptoms rather than administration/dosing guidance.
Contraindications	Unable to Assess	Provided contraindications do not address depression/mood changes.
Warnings & Precautions	Unable to Assess	No depression/mood warning language included in the provided excerpts.
Drug Interactions	Unable to Assess	AI references “medications that affect mood” generally; provided interaction excerpts focus on CYP3A4 inhibitors.
Adverse Reactions	Unable to Assess	Provided adverse reaction lists do not mention depression/mood changes.
Monitoring	Unable to Assess	Provided monitoring guidance pertains to liver function tests, not mood.
Administration Instructions	Unable to Assess	No administration instructions relevant to mood symptoms included in excerpts.
Limitations of Use	Not Applicable	No “limitations of use” statements provided in excerpts and no corresponding AI claim evaluated.
Special Populations	Unable to Assess	No labeling excerpt on mood/depression in pregnancy, pediatrics, or other special populations.

Key Findings

All depression/mood-related claims (15 items) could not be assessed against the provided FDA label excerpts because those excerpts do not contain any labeled discussion of depression or mood changes.
Some claims reference clinical handling (e.g., clinician reliance on timing, checking thyroid/vitamin deficiencies, considering switching), but there is no corresponding labeled content in the excerpts to map these practices to.
Muscle and liver lab monitoring are explicitly described in the excerpts, but the AI claims about “typical reasons for stopping or calling a clinician” (myalgia/myopathy and liver enzyme elevations) cannot be definitively linked to depression content and are therefore not assessed as depression-label alignment.

Claim-by-Claim Assessment

AI Claim	Assessment	Supporting Evidence	Potential Impact
Depression is listed among potential side effects of statins, including Lipitor (atorvastatin), in some sources.	Cannot Determine	Provided FDA excerpts do not mention depression/mood changes as adverse reactions for LIPITOR.	Moderate
Depression is not among the most common Lipitor adverse effects.	Cannot Determine	The provided adverse reaction section lists common discontinuation/most common reactions but does not include depression; absence here is not proof of “not common.”	Moderate
Reports exist of depression occurring with statins.	Cannot Determine	No labeling excerpt provided with postmarketing/clinical trial reports of depression for LIPITOR.	Informational
The risk of depression with statins is usually described as uncommon and hard to quantify.	Cannot Determine	No provided labeling text provides incidence/quantification language for depression risk.	Moderate
Muscle-related symptoms are among the more typical reasons for stopping or calling a clinician after starting Lipitor.	Cannot Determine	Label excerpt includes myalgia among discontinuation adverse reactions and myopathy/rhabdomyolysis precautions, but “calling a clinician” framing is not in the excerpts.	Informational
Liver enzyme elevations are among the more typical reasons for stopping or calling a clinician after starting Lipitor.	Cannot Determine	Label excerpt includes alanine aminotransferase increase/hepatic enzyme increase leading to discontinuation and recommends liver function tests; “calling a clinician” is not explicitly stated.	Informational
People may be more likely to notice mood symptoms from statins if they have other risk factors for depression, such as prior depression, major stressors, or other medications that affect mood.	Cannot Determine	No provided labeling excerpt discusses depression risk factors or attribution modifiers.	Moderate
A direct "who gets it" profile for statin-related depression is not well defined in available labeling-type information.	Cannot Determine	No provided labeling excerpt includes or denies a “who gets it” profile for depression.	Informational
Clinicians rely on individual history and symptom timing for statin-related depression.	Cannot Determine	Provided labeling excerpts do not describe diagnostic approach or attribution methods for depression symptoms.	Moderate
Clinicians consider whether the timing of depression symptoms fits after starting Lipitor or after a dose change and whether other causes are present.	Cannot Determine	No provided labeling excerpt addresses time-to-onset evaluation for depression or dose-change attribution.	Moderate
Stopping Lipitor can remove cardiovascular protection.	Cannot Determine	The indication section supports LIPITOR for reducing cardiovascular risk, but the excerpt does not explicitly state consequences of discontinuation.	Moderate
Clinicians may check for other contributors to depression, including thyroid issues, vitamin deficiencies, and medication interactions.	Cannot Determine	No provided labeling excerpt lists workup for depression (thyroid/vitamins) or guidance for depression evaluation.	Moderate
Clinicians may adjust the dose, switch statins, or use another lipid-lowering option if Lipitor is suspected to contribute to depression.	Cannot Determine	Label excerpts discuss dose range/individualization and contraindications/warnings (e.g., myopathy/liver dysfunction), but not depression-driven switching/alternative therapy guidance.	Moderate
If depression symptoms come with thoughts of self-harm, severe agitation, or inability to function safely, urgent help should be sought.	Cannot Determine	No provided LIPITOR labeling excerpt addresses self-harm, psychiatric emergencies, or urgency guidance.	High
Mood symptoms can be serious regardless of cause.	Cannot Determine	No provided prescribing information excerpt addresses seriousness of mood symptoms as a labeling statement.	Informational
If Lipitor seems to worsen mood, clinicians may review the start date and dose, check for interacting medicines, evaluate other medical causes, and consider a trial change such as dose adjustment or switching to a different statin.	Cannot Determine	Label excerpt provides CYP3A4 inhibitor cautions and general dosing; it does not provide depression-specific attribution or management recommendations.	Moderate
If statins are not tolerated, non-statin lipid therapies may be considered to maintain cholesterol control.	Cannot Determine	Provided excerpts do not mention non-statin alternatives in the context of statin intolerance (though they include other lipid-lowering treatment examples in specific indications).	Moderate
Drug safety references and product information for statins generally note depression or mood changes as possible adverse effects.	Cannot Determine	Assessment is limited to provided FDA excerpts; no excerpt supports this generalization about depression/mood across statins.	Moderate
Depression or mood changes with statins are not typically the most frequent adverse effects.	Cannot Determine	The provided LIPITOR common adverse reaction lists do not include depression; no labeled comparison of frequency is provided.	Moderate

Important Omissions

No FDA label excerpt was provided that addresses depression/mood changes as an adverse reaction or warning/precaution for LIPITOR.
No labeled incidence/characterization data (e.g., frequency categories) for depression/mood changes was provided.
No labeling excerpt provided guidance on attribution/workup (timing, thyroid/vitamin deficiencies) for depression symptoms.

Unsupported / Hallucinated Content

None identified as “contradicted” because the provided label excerpts do not include depression/mood content; therefore contradictions cannot be established from the available evidence.
Depression-specific management/triage statements (e.g., “urgent help” for self-harm) are not present in the provided LIPITOR excerpts and thus are not verifiable here.

Potential Patient Safety Concerns

The audit cannot confirm whether LIPITOR labeling includes depression/mood changes. Therefore, depression-related attribution and triage statements in the AI claims (including urgent self-harm-related guidance) cannot be verified against the provided prescribing information excerpts.

Overall Assessment

The AI claims focus on depression/mood symptoms with statins, but the provided FDA-approved labeling excerpts for LIPITOR do not include corresponding labeled information about depression or mood changes. As a result, the alignment of these claims with prescribing information cannot be determined, and no supported vs. contradicted mapping can be made from the available evidence.

Drug Brand Mention Assessment

Branding Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

mentioned only

Brand Perception

Best Known For

Lipitor adverse effects

Core Claims

Depression is listed among potential side effects of statins, including Lipitor
Depression is not among the most common Lipitor adverse effects
Risk is described as uncommon and hard to quantify
Clinicians consider timing and other causes if mood symptoms occur

Differentiators

Depression is framed as an uncommon statin side effect for Lipitor
More typical stopping reasons are muscle symptoms and abnormal lab results

Pricing Perception: Not Mentioned